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Background: Only a few biomarkers are available for assessing disease activity in systemic
lupus erythematosus (SLE). Mean platelet volume (MPV) has been recently studied as an
inﬂammatory biomarker. It is currently unclear whether MPV may also play a role as a
biomarker of disease activity in adult patients with SLE.
Objective: We investigated the association between MPV and disease activity in adult
patients with SLE.
Methods: In this retrospective study, we compared two groups of adult patients divided
according to disease activity (36 per group). Subjects were age- and gender-matched.
Results: MPV was signiﬁcantly decreased with respect to those of inactive patients
(7.16 ± 1.39 vs. 8.16 ± 1.50, p = 0.005). At a cutoff level of 8.32 fL, MPV has a sensitivity of
86%  and a speciﬁcity of 41% for the detection of disease activity. A modest positive cor-
relation was found between MPV and albumin (r = 0.407, p = 0.001), which in turn is inversely
associated with disease activity.
Conclusions: In summary, MPV is decreased in adult patients with active lupus disease, and
positively correlated with albumin, another biomarker of disease activity. Prospective stud-ies are needed to evaluate the prognostic value of this biomarker.
© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).∗ Corresponding author.
E-mail: grdelgadog@gmail.com (G. Delgado-García).
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2255-5021/© 2016 Elsevier Editora Ltda. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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O  volume  plaquetário  médio  está  reduzido  em  adultos  com  lúpus  ativo
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r  e  s  u  m  o
Antecedentes: Existem poucos biomarcadores disponíveis para avaliar a atividade da doenc¸a
no  lúpus eritematoso sistêmico (LES). O volume plaquetário médio (VPM) foi recentemente
estudado como um biomarcador inﬂamatório. Atualmente não está claro se o VPM também
pode desempenhar um papel como um biomarcador da atividade da doenc¸a em pacientes
adultos com LES.
Objetivo: Investigou-se a associac¸ão entre o VPM e a atividade da doenc¸a em pacientes
adultos com LES.
Métodos: Neste estudo retrospectivo, compararam-se dois grupos de pacientes adultos divi-
didos de acordo com a atividade da doenc¸a (36 por grupo). Os indivíduos foram pareados
por  idade e gênero.
Resultados: O VPM esteve signiﬁcativamente diminuído nos pacientes com doenc¸a ativa em
comparac¸ão com os níveis em pacientes com doenc¸a inativa (7,16 ± 1,39 versus 8,16 ± 1,50,
p  = 0,005). Em um nível de corte de 8,32 fL, o VPM tem uma sensibilidade de 86% e uma
especiﬁcidade de 41% para a detecc¸ão da atividade da doenc¸a. Encontrou-se uma  correlac¸ão
positiva modesta entre o VPM e a albumina (r = 0,407, p = 0,001), que por sua vez está inver-
samente associada à atividade da doenc¸a.
Conclusões: Em resumo, o VPM está diminuído em pacientes adultos com lúpus ativo, e
positivamente correlacionado com a albumina, outro biomarcador da atividade da doenc¸a.
São necessários estudos prospectivos para avaliar o valor prognóstico desse biomarcador.
©  2016 Elsevier Editora Ltda. Este e´ um artigo Open Access sob uma  licenc¸a CC
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latelet size correlates with platelet activity. Autoimmune
eactions are thought to contribute to platelet activation in
ystemic lupus erythematosus (SLE). In fact, there is a corre-
ation between mean platelet volume (MPV) values and active
nﬂammatory diseases.1,2 It has been recently reported that
PV  is increased in patients with juvenile SLE. Moreover, this
arameter increased in parallel with the activity index, and
ppears to be more  accurate than erythrocyte sedimentation
ate (ESR) and C3 in detecting disease activity.3 However, it
s currently unclear whether MPV  may also play a role as a
iomarker of disease activity in adult patients with SLE. There-
ore, we conducted the present study to test this hypothesis.
aterial  and  methods
ubjects  and  study  design
 retrospective, cross-sectional, comparative design was used
or this study. Demographic and laboratory data were obtained
y reviewing medical records of all patients who had been
iagnosed with SLE in our hospital. Systemic Lupus Inter-
ational Collaborating Clinics (SLICC) classiﬁcation criteria
ere used for the diagnosis, except for those patients who
ere diagnosed before these criteria were published, in which
ase it was made using the American College of Rheumato-
ogy (ACR) criteria. Lupus nephritis was classiﬁed according
o the International Society of Nephrology/Renal Pathology
ociety (ISN/RPS) 2003 classiﬁcation. The inclusion crite-
ia were as follows: age older than 16 years; diagnosis ofBY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
SLE; and a Mexican Systemic Lupus Erythematosus Disease
Activity Index (Mex-SLEDAI) scored in the polyclinic (inac-
tive patients) or at admission (active patients), as recorded
by a rheumatology fellow. Exclusion criteria were the follow-
ing: infection, thrombocytopenia, rheumatoid arthritis (RA),
ankylosing spondylitis (AS), inﬂammatory bowel disease (IBD),
psoriasis, and incomplete medical record. Overall disease
activity was assessed with Mex-SLEDAI. Patients scoring <2
were classiﬁed as inactive, while those scoring >5 were clas-
siﬁed as active.4,5 This study was approved by the ethics
committee of the Autonomous University of Nuevo León Fac-
ulty of Medicine. Written informed consent was not required.
Assays
Blood samples were taken by from both plain and EDTA  tubes.
The latter were used for complete blood count (CBC). Most rou-
tine CBC were done with a Cell-Dyn Ruby analyzer (Abbott
Diagnostics, USA), while most clinical chemistry parameters
(creatinine, blood urea nitrogen and serum albumin) were
measured using a DxC800 Synchron analyzer (Beckman Coul-
ter, USA). ESR determinations were performed by the Wintrobe
method, whose upper normal limit was 20 mm/h.
Statistics
Based on a previous report on MPV in juvenile SLE,3 sample
size was calculated using comparisons of means. Calcula-
tion was performed using  ˛ = 0.05,  ˇ = 0.20, and two  tails.
A total sample size of 60 (30 in each group) would be
required to demonstrate a statistically signiﬁcant differ-
ence between groups. Data were ﬁrst analyzed for normality
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Fig. 1 – Receiver-operating characteristics (ROC) curve
analysis for the diagnostic performance of ESR (blue line),506  r e v b r a s r e u m a t
using Shapiro–Wilk test. Comparisons between groups were
performed by using chi-square test, Student’s t-test or
Mann–Whitney U test, as appropriate. Associations between
the variables were explored using the Pearson product-
moment correlation coefﬁcient or Spearman’s rho. A receiver
operating characteristic (ROC) curve was generated to deter-
mine the cutoff value in the MPV  (and other inﬂammatory
biomarkers) with the highest level of accuracy in identifying
patients with disease activity. Sensitivity, speciﬁcity, positive
predictive value (PPV), and negative predictive value (NPV)
were calculated. Unless indicated otherwise, all results are
expressed as mean ± SD or median (25–75%). Statistical analy-
ses were conducted using SigmaStat (v. 3.5, Erkrath, Germany)
or MedCalc (v. 14.12.0, Ostend, Belgium), and a p-value below
0.05 (p < 0.05) was considered signiﬁcant.
Results
A total of 72 patients were included in this study, 36 patients
were classiﬁed as having active disease (34 females, aged 18–64
years), and 36 patients as having inactive disease (35 females,
aged 20–53 years). The age and gender distributions were sim-
ilar in the two groups (p = 0.83 and p = 0.55, respectively). 10
active patients (27%) were diagnosed during their ﬁrst hospi-
talization, so years since diagnosis were signiﬁcantly different
between groups (1 [0–15] vs.  5 [1–23], p ≤ 0.001). The percent-
age of a previous diabetes diagnosis did not differ by disease
activity ([1, n = 70] = 2.57, p = 0.108, Yates’ p-value). Patients with
active disease were more  likely to have a previous hyperten-
sion diagnosis than those with inactive disease (38.2% vs.  2.7%,
[1, n = 70] = 13.74, p ≤ 0.001). Ten (27.7%) of the active patients
had biopsy-proven lupus nephritis (LN). Of these, 40% had
ISN/RPS class III LN, 30% had class IV LN, 20% had class V LN,
and 10% had class II LN.Hemoglobin, absolute lymphocyte count (LYM), MPV, and
albumin of active patients were signiﬁcantly decreased with
respect to those of inactive patients, whereas ESR was com-
paratively increased in the former group. Platelet count and
Table 1 – Paraclinical comparison between groups.
Parameter Active (n = 36) 
Hb (g/dL) 10.9 ± 1.97 
WBC (109/L) 6.46 ± 2.73 
NEU (109/L) 4.81 ± 2.36a
LYM (109/L) 1.12 ± 0.74a
PLT (109/L) 269.88 ± 870.02 2
MPV (fL) 7.16  ± 1.39 
ESR (mm/h) 31 (21.5–45) 
Crea (mg/dL) 0.61 (0.57–0.89)a
BUN (mg/dL) 13.4 (10–22.75)a
Alb (g/dL) 2.73 ± 0.81b
Hb, hemoglobin; WBC, white blood cell count; NEU, absolute neutrophil co
platelet volume; ESR, erythrocyte sedimentation rate; Crea, creatinine; B
Mann–Whitney U test.
All results are expressed as mean ± SD or median (25–75%).
a n = 35.
b n = 32.MPV (green line) and albumin (Alb, orange line).
creatinine were not signiﬁcantly different between groups
(Table 1). A modest positive correlation was found for MPV
and albumin in active patients (r = 0.407, p = 0.001). There were
no signiﬁcant relationships between MPV and ESR (p = 0.26).
The ROC curve analysis for MPV showed an area under the
curve (AUC) of 0.685 (95% CI 0.565–0.790, p = 0.003) with an opti-
mal  cutoff value of 8.32 fL (Fig. 1). Sensitivity, speciﬁcity, PPV,
and NPV were 86%, 41%, 59%, and 75%, respectively. The AUC
for predicting disease activity was 0.658 (95% CI 0.537–0.766,
p = 0.015) for ESR (Fig. 1). At a cutoff level of 37 mm/h, sen-
sitivity, speciﬁcity, PPV, and NPV were 44%, 86%, 76%, and
60%, respectively. The AUC for albumin, with a cutoff point
of 3.2 g/dL, was 0.845 (95% CI 0.737–0.922, p ≤ 0.001) (Fig. 1).
Inactive (n = 36) p Test
12.69 ± 1.2 <0.001 ST
6.28 ± 2.76 0.781 ST
4.12 ± 2.49 0.237 ST
1.58 ± 0.67 0.008 ST
71.72 ± 698.07 0.922 ST
8.16 ± 1.50 0.005 ST
22.5 (14.5–34.5) 0.021 MWU
0.64 (0.53–0.72) 0.60 MWU
12 (10–14) 0.12 MWU
3.7 ± 0.27 <0.001 ST
unt; LYM, absolute lymphocyte count; PLT, platelet count; MPV, mean
UN, blood urea nitrogen; Alb, albumin; ST, Student’s t-test; MWU,
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ensitivity, speciﬁcity, PPV, and NPV were 75%, 97.2%, 96%, and
1%, respectively. The pairwise comparison among the ROC
urves showed no statistical difference (p = 0.054 and p = 0.947,
espectively).
iscussion
ontrary to previously reported ﬁndings in juvenile SLE,3 in
his study the MPV  was found to be signiﬁcantly lower in adult
atients with active disease compared to those classiﬁed as
aving inactive disease. Although several reports have indi-
ated the potential link between higher MPV  values and active
nﬂammatory disease, the opposite has been found in other
tudies.1,2 In the largest sample to date, MPV was decreased in
dult patients with active RA, and increased after treatment.6
 recent review did not include this report.7 In a small retro-
pective study of 30 adult patients with active AS, MPV was
ecreased when initial tests were performed, and increased
fter treatment.8 Notwithstanding, this ﬁnding was not repro-
uced in a larger study.9 Adult patients with IBD (both in active
nd remission stages) also have a lower MPV  when compared
o control group.10 Likewise, in children with acute rheumatic
ever, MPV  has been reported as decreased, and increased after
reatment.11
Platelet activation is observed in patients with SLE, and its
athophysiology could include inﬂammatory cytokines and
omplement.12,13 One plausible mechanism to explain the
ssociation between decreased MPV  and disease activity could
e the consumption of large activated platelets in extravascu-
ar sites of inﬂammation.1 However, while platelet activation
s enhanced in patients with SLE, these patients have normal
alues for platelet mean life-span,14 suggesting that platelet
onsumption is minimal. More  studies are needed in order to
urther elucidate the cause of this reduction in platelet size.
Serum albumin was comparatively lower in those with
ctive disease. A modest positive correlation was found
etween MPV  and albumin, which in turn is inversely asso-
iated with disease activity.15 ESR was signiﬁcantly elevated
n patients with active disease. This is in line with exist-
ng literature, since ESR elevations have been associated with
verall disease activity.16 Interestingly, we found no corre-
ation between ESR and MPV.  Even though both parameters
ight evaluate disease activity, this lack of correlation could
e, in part, because these biomarkers may reﬂect two separate
iological processes.
Only a few biomarkers are available for assessing disease
ctivity in SLE. An ideal biomarker must be easily measured,
eproducible and sensitive to changes in disease activity.17
n this study, there was no signiﬁcant difference in over-
ll accuracy between MPV  and ESR for detection of disease
ctivity. Besides being a widely available test, MPV is also cost-
ffective. At a cutoff level of 8.32 fL, MPV  has a high sensitivity
86%) for the detection of disease activity. A highly sensitive
est is chieﬂy important when it is used to identify a serious
ut treatable condition (as a lupus ﬂare).This is the ﬁrst study, to our knowledge, to speciﬁcally
xamine the relationship between MPV  and disease activity
n adult patients with SLE. Various authors have identiﬁed a
revious study that found decreased MPV  in adult patients
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with SLE.1,3 Nonetheless, the aforementioned study was not
intended to demonstrate that MPV is associated with disease
activity, since its truly aim was to compare the performance
of two automated cell counters.18
The time delay between sampling and processing was not
controlled in our study. However, we found a decreased MPV
in adult patients with active disease, and MPV  increases (not
decreases) over time in EDTA tubes.2 Phlebotomists and lab-
oratory technicians were blind to the clinical status of the
patient, thus rationally excluding bias. Also, the diagnosis of
hypertension was more  frequent in patients with active dis-
ease, yet this would most likely not affect our results, because
hypertension is associated with an increased MPV,  and not
with its decrease.19,20
In summary, MPV is decreased in adult patients with active
lupus disease, and positively correlated with serum albumin,
another biomarker of disease activity. Prospective studies are
needed to evaluate the prognostic value of this biomarker.
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. Gasparyan AY, Ayvazyan L, Mikhailidis DP, Kitas GD. Mean
platelet volume: a link between thrombosis and
inﬂammation? Curr Pharm Des. 2011;17:47–58.
2. Leader A, Pereg D, Lishner M. Are platelet volume indices of
clinical use? A multidisciplinary review. Ann Med.
2012;44:805–16.
3. Yavuz S, Ece A. Mean platelet volume as an indicator of
disease activity in juvenile SLE. Clin Rheumatol.
2014;33:637–41.
4. Guzmán J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J,
Alarcón-Segovia D. Measurement of disease activity in
systemic lupus erythematosus. Prospective validation of 3
clinical indices. J Rheumatol. 1992;19:1551–8.
5. Arce-Salinas A, Cardiel MH, Guzmán J, Alcocer-Varela J.
Validity of retrospective disease activity assessment in
systemic lupus erythematosus. J Rheumatol. 1996;23:846–9.
6. Kim DA, Kim TY. Controversies over the interpretation of
changes of mean platelet volume in rheumatoid arthritis.
Platelets. 2011;22:79–80.
7. Beinsberger J, Heemskerk JW,  Cosemans JM.  Chronic arthritis
and cardiovascular disease: altered blood parameters give
rise to a prothrombotic propensity. Semin Arthritis Rheum.
2014;44:345–52.
8. Kisacik B, Tufan A, Kalyoncu U, Karadag O, Akdogan A, Ozturk
MA, et al. Mean platelet volume (MPV) as an inﬂammatory
marker in ankylosing spondylitis and rheumatoid arthritis. Jt
Bone Spine. 2008;75:291–4.
9. Yazici S, Yazici M, Erer B, Erer B, Calik Y, Bulur S, et al. The
platelet functions in patients with ankylosing spondylitis:
anti-TNF-alpha therapy decreases the mean platelet volume
and platelet mass. Platelets. 2010;21:126–31.
0. Öztürk ZA, Dag MS, Kuyumcu ME, Cam H, Yesil Y, Yilmaz N,
et al. Could platelet indices be new biomarkers for
inﬂammatory bowel diseases? Eur Rev Med Pharmacol Sci.
2013;17:334–41.
1. Sert A, Aypar E, Odabas D. Mean platelet volume in acute
rheumatic fever. Platelets. 2013;24:378–82.
 o l . 2
1
1
1
1
1
1
1
1508  r e v b r a s r e u m a t
2. Boilard E, Blanco P, Nigrovic PA. Platelets: active players in the
pathogenesis of arthritis and SLE. Nat Rev Rheumatol.
2012;8:534–42.
3. Habets KL, Huizinga TW, Toes RE. Platelets and
autoimmunity. Eur J Clin Invest. 2013;43:746–57.
4. Kutti J, Bergström AL. Platelet kinetics in systemic lupus
erythematosus (SLE), with special reference to corticosteroid
and  azathioprine therapy. Scand J Rheumatol. 1981;10:266–8.
5. Yip J, Aghdassi E, Su J, Lou W,  Reich H, Bargman J, et al. Serum
albumin as a marker for disease activity in patients with
systemic lupus erythematosus. J Rheumatol. 2010;37:1667–72.
6. Stojan G, Fang H, Magder L, Petri M. Erythrocyte
sedimentation rate is a predictor of renal and overall SLE
disease activity. Lupus. 2013;22:827–34.
2 0 1 6;5 6(6):504–508
7. Jung JY, Bae CB, Suh CH. Promising biomarkers for systemic
lupus erythematosus. Expert Opin Med Diagn. 2013;7:601–13.
8. Turner-Stokes L, Jones D, Patterson KG, Todd-Pokropek A,
Isenberg DA, Goldstone AH. Measurement of haematological
indices of chronic rheumatic disease with two newer
generation automated systems, the H1 and H6000
(Technicon). Ann Rheum Dis. 1991;50:583–7.
9. Varol E, Akcay S, Icli A, Yucel H, Ozkan E, Erdogan D, et al.
Mean platelet volume in patients with prehypertension and
hypertension. Clin Hemorheol Microcirc. 2010;45:67–72.0. Gasparyan AY, Stavropoulos-Kalinoglou A, Toms TE, Douglas
KM, Kitas GD. Association of mean platelet volume with
hypertension in rheumatoid arthritis. Inﬂamm Allergy Drug
Targets. 2010;9:45–50.
